Yeni Tüberküloz Aşıları

Authors

Orhan Baylan
https://orcid.org/0000-0002-6529-7824

References

An Y, Ni R, Zhuang L, et al. Tuberculosis vaccines and therapeutic drug: challenges and future directions. Mol Biomed 2025;6(1):4.

https://iris.who.int/server/api/core/bitstreams/7292c91e-ffb0-4cef-ac39-0200f06961ea/content (erişim tarihi: 16.03.2026)

Groschel MI, Sayes F, Shin SJ, et al. Recombinant BCG expressing ESX-1 of Mycobacterium marinum combines low virulence with cytosolic immune signaling and improved TB protection. Cell Rep 2017;18(11):2752-65.

Maani AA, Petersen E, Memish ZA. The critical role of new tuberculosis vaccines in achieving the WHO 2035 End TB target. IJID Reg 2025;14(Suppl 2):100595.

https://www.stoptb.org/sites/default/files/imported/document/BCG_press_release_Final.pdf (erişim tarihi: 16.03.2026)

Rota S. BCG’nin saltanatı bitiyor mu? Yeni aşı arayışları. In: Tüberküloz. Eds.: Gönenç Ortaköylü M, Özlü T. Güncel Göğüs Hastalıkları Serisi Kitapları, Akciğer Sağlığı ve Yoğun Bakım Derneği (ASYOD), Dünya Tıp Kitabevi, 63-78, 2021, ISBN: 978-605-9615-71-6.

von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010;24(5):675-85.

Vasiliu A, Martinez L, Gupta RK, et al. Tuberculosis prevention: current strategies and future directions. Clin Microbiol Infect 2024;30(9):1123-30.

Zhuang L, Ye Z, Li L, et al. Next-generation TB vaccines: progress, challenges, and prospects. Vaccines (Basel) 2023;11(8):1304.

Yang Y, Chen YZ, Xia T. Optimizing antigen selection for the development of tuberculosis vaccines. Cell Insight 2024;3(3):100163.

Stockdale L, Fletcher H. The future of vaccines for tuberculosis. Clin Chest Med 2019;40(4):849-56.

Gong W, Liang Y, Mi J, et al. Peptides-based vaccine MP3RT induced protective immunity against Mycobacterium tuberculosis infection in a humanized mouse model. Front Immunol 2021;12(1393):666290.

Sharma SK, Katoch K, Sarin R, et al. Efficacy and safety of Mycobacterium indicus pranii as an adjunct therapy in category II pulmonary tuberculosis in a randomized trial. Sci Rep 2017;7(1):3354.

Jeyanathan M, Fritz DK, Afkhami S, et al. Aerosol delivery, but not intramuscular injection, of adenovirus vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans. JCI Insight 2022;7(3):e155655.

Broset E, CalvetSeral J, et al. Engineering a new vaccine platform for heterologous antigen delivery in live-attenuatedMycobacterium tuberculosis. ComputStruct Biotechnol J 2021;19:4273-83.

Singh AK, Netea MG, Bishai WR. BCG turns 100: itsnontraditionaluses against viruses, cancer, and immunologic diseases. J Clin Invest 2021;131(11):e148291.

Gong W, Pan C, Cheng P, et al. Peptide-based vaccines for tuberculosis. Front Immunol 2022;13:830497.

Yamaguchi T, Samukawa N, Matsumoto S, et al. BCG-derived acellular membrane vesicles elicit antimycobacterial immunity and innate immune memory. Front Immunol 2025;16:1534615.

Bouzeyen R, Chugh S, Gosain TP, et al. Co-administration of anticancer candidate MK-2206 enhances the efficacy of BCG vaccine against Mycobacterium tuberculosis in mice and guinea pigs. Front Immunol 2021;12:645962.

Gong W, Liang Y, Wu X. The current status, challenges, and future developments of new tuberculosis vaccines. Hum Vacc Immunother 2018;14(7):1697-716.

Singh Y, Kohli S, Sowpati DT, et al. Gene cooption in mycobacteria and search for virulence attributes: comparative proteomic analyses of Mycobacterium tuberculosis, Mycobacterium indicus pranii and other mycobacteria. Int J Med Microbiol 2014;304(5–6):742-8.

Sharma A, Saqib M, Sheikh JA, et al. Mycobacterium indicus pranii protein MIP05962 induces Th1 cell mediated immune response in mice. Int J Med Microbiol 2018;308(8):1000-8.

Kumar P, John V, Marathe S, et al. Mycobacterium indicus pranii induces dendritic cell activation, survival, and Th1/Th17 polarization potential in a TLR-dependent manner. J Leukoc Biol 2015;97(3):511-20.

Gupta A, Geetha N, Mani J, et al. Immunogenicity and protective efficacy of “Mycobacterium w” against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route. Infect Immunity 2009;77(1):223-31.

Saqib M, Khatri R, Singh B, et al. Mycobacterium indicus pranii as a booster vaccine enhances BCG induced immunity and confers higher protection in animal models of tuberculosis. Tuberculosis (Edinb) 2016;101:164-73.

Gupta A, Ahmad FJ, Ahmad F, et al. Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One 2012;7(7):e39215.

Katoch K, Singh P, Adhikari T, et al. Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Vaccine 2008;26(9):1228-34.

Munseri P, Said J, Amour M, et al. DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial. Vaccine 2020;38(46):7239-45.

Masonou T, Hokey DA, Lahey T, et al. CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: a randomized, placebo-controlled trial. PLoS One 2019;14(5):e0217091.

Fatima S, Kumari A, Das G, et al. Tuberculosis vaccine: A journey from BCG to present. Life Sci 2020;252:117594.

Guirado E, Gil O, Caceres N, et al. Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis. Clin Vaccine Immunol 2008;15(8):1229-37.

Lahey T, Laddy D, Hill K, et al. Immunogenicity and protective efficacy of the DAR-901 booster vaccine in a murine model of tuberculosis. PLoS One 2016;11(12):e0168521.

von Reyn CF, Lahey T, Arbeit RD, et al. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: a randomized, controlled trial of DAR-901. PLoS One 2017;12(5):e0175215.

Usman MM, Ismail S, Teoh TC. Vaccine research and development: tuberculosis as a global health threat. Cent Eur J Immunol 2017;42(2):196-204.

Whitlow E, Mustafa AS, Hanif SNM. An overview of the development of new vaccines for tuberculosis. Vaccines 2020;8(4):586.

Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (Edinb) 2006;86(3–4):273-89.

Vilaplana C, Montane E, Pinto S, et al. Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine 2010;28(4):1106-16.

Nell AS, D’Lom E, Bouic P, et al. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One 2014;9(2):e89612.

Gong WP, Liang Y, Ling YB, et al. Effects of Mycobacterium vaccae vaccine in a mouse model of tuberculosis: protective action and differentially expressed genes. Mil Med Res 2020;7(1):25.

Skinner MA, Yuan S, Prestidge R, et al. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun 1997;65(11):4525-30.

Onyebujoh PC, Abdulmumini T, Robinson S, et al.Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis underdifficultconditions in Africa. Respir Med 1995;89(3):199-207.

Corlan E, Marica C, Macavei C, et al. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease. Respir Med 1997;91(1):21-9.

DurbanImmunotherapy Trial Group. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: A randomised controlled trial. Lancet 1999;354(9173):116-9.

Mwinga A, Nunn A, Ngwira B, et al. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: A randomised placebo-controlled trial. Lancet 2002;360(9339):1050-5.

Huang, CY, Hsieh WY. Efficacy of Mycobacterium vaccaeimmunotherapy for patients with tuberculosis: A systematic review and meta-analysis. Hum Vaccines Immunother 2017;13(9):1960-71.

Vuola JM, Ristola MA, Cole B, et al. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS 2003;17(16):2351-5.

Waddell RD, Chintu C, Lein AD, et al. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis 2000;30(Suppl 3):309-15.

Lahey T, Arbeit RD, Bakari M, et al. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine 2010;28(48):7652-8.

Li J, Zhao A, Tang J, et al. Tuberculosis vaccine development: from classic to clinical candidates. Eur J Clin Microbiol Infect Dis 2020;39(8):1405-25.

WHO. Global tuberculosis report 2017. Geneva: World Health Organization;2017. p.1-262.

Flores-Valdez MA, Kupz A, Subbian S. Recent developments in mycobacteria-based live attenuated vaccine candidates for tuberculosis. Biomedicines 2022;10(11):2749.

Andersen P, Scriba TJ. Moving tuberculosis vaccines from theory to practice. Nat Rev Immunol 2019;19(9):550-62.

Foreman TW, Veatch AV, LoBato DN, et al. Non-pathologic infection of macaques by an attenuated mycobacterial vaccine is not reactivated in the setting of HIV co-infection. Am J Pathol 2017;187(12):2811-20.

Kaushal D, Foreman TW, Gautam US, et al. Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis. Nat Commun 2015;6:8533.

Sakthi S, Palaniyandi K, Gupta UD, et al. Lipoprotein LpqS deficient M.tuberculosis mutant is attenuated for virulence in vivo and shows protective efficacy better than BCG in guinea pigs. Vaccine 2016;34(6):735-43.

Kim BJ, Kim BR, Kook YH, et al. A temperature sensitive Mycobacterium paragordonae induces enhanced protective immune responses against mycobacterial infections in the mouse model. Sci Rep 2017;7(1):15230.

Martín C, Aguiló N, Marinova D, et al. Update on TB vaccine pipeline. Appl Sci 2020;10(7):2632.

Lacamara S, Martin C. MTBVAC: a tuberculosis vaccine candidate advancing towards clinical efficacy trials in TB prevention. Arch Broncopneumol 2023;59(12):821-8.

Tarancon R, Dominguez-Andres J, Uranga S, et al. New live attenuated tuberculosis vaccine MTBVAC induces trained immunity and confers protection against experimental lethal pneumonia. PLoS Pathog 2020;16(4):e1008404.

White AD, Sibley L, Sarfas C, et al. MTBVAC vaccination protects Rhesus macaques against aerosol challenge with M.tuberculosis and induces immune signatures analogous to those observed in clinical studies. NPJ Vaccines 2021;6(1):4.

Spertini F, Audran R, Chakour R, et al. Safety of human immunization with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med 2015;3(12):953-62.

Tameris M, Mearns H, Penn-Nicholson A, et al. Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respir Med 2019;7(9):757-70.

Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 2014;58(4):470-80.

Lange C, Aaby P, Behr MA, et al. 100 years of Mycobacterium bovis bacille Calmette-Guerin. Lancet Infect Dis 2022;22(1):e2-12.

Dintwe OB, Ballweber Fleming L, Voillet V, et al. Adolescent BCG revaccination induces a phenotypic shift in CD4(+) T cell responses to Mycobacterium tuberculosis. Nat Commun 2024;15(1):5191.

Lawrence A. Bacillus Calmette-Guérin (BCG) revaccination and protection against tuberculosis: a systematic review. Cureus 2024;16(3):e56643.

Bekker LG, Dintwe O, Fiore-Gartland A, et al. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. EClinicalMedicine 2020;21:100313.

Ohara N, Yamada T. Recombinant BCG vaccines. Vaccine 2001;19(30):4089-98.

Flores-Valdez MA. After 100 years of BCG immunization against tuberculosis, what is new and still outstanding for this vaccine? Vaccines (Basel) 2021;10(1):57.

Yuan X, Teng X, Jing Y, et al. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection. Appl Microbiol Biotechnol 2015;99(24):10587-95.

Kwon KW, Aceves-Sanchez MJ, Segura-Cerda CA, et al. BCGΔBCG1419c increased memory CD8(+) T cell-associated immunogenicity and mitigated pulmonary inflammation compared with BCG in a model of chronic tuberculosis. Sci Rep 2022;12(1):15824.

Aceves-Sanchez MJ, Flores-Valdez MA, Pedroza-Roldan C, et al. Vaccination with BCGΔBCG1419c protects against pulmonary and extrapulmonary TB and is safer than BCG. Sci Rep 2021;11(1):12417.

Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 2005;115(9):2472-9.

Kaufmann SHE. Vaccination against tuberculosis: revamping BCG by molecular genetics guided by immunology. Front Immunol 2020;11:316.

Hess J, Miko D, Catic A, et al. Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA 1998;95(9):5299-304.

Velmurugan K, Grode L, Chang R, et al. Nonclinical development of BCG replacement vaccine candidates. Vaccines (Basel) 2013;1(2):120-38.

Farinacci M, Weber S, Kaufmann SH. The recombinant tuberculosis vaccine rBCG ΔureC::hly(+) induces apoptotic vesicles for improved priming of CD4(+) and CD8(+) T cells. Vaccine 2012;30(52):7608-14.

Nieuwenhuizen NE, Kulkarni PS, Shaligram U, et al. The recombinant bacille Calmette-Guerin vaccine VPM1002: ready for clinical efficacy testing. Front Immunol 2017;8:1147.

Zhu B, Dockrell HM, Ottenhoff THM, et al. Tuberculosis vaccines: Opportunities and challenges. Respirology 2018;23(4):359-68.

Loxton AG, Knaul JK, Grode L, et al. Safety and immunogenicity of the recombinant Mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa. Clin Vaccine Immunol 2017;24(2).

Brisse M, Vrba SM, Kirk N, et al. Emerging concepts and technologies in vaccine development. Front Immunol 2020;11:583077.

Bellini C, Horváti K. Recent advances in the development of protein- and peptide-based subunit vaccines against tuberculosis. Cells 2020;9(12):2673.

Moradi M, Vahedi F, Abbassioun A, et al. Liposomal delivery system/adjuvant for tuberculosis vaccine. Immun Inflamm Dis 2023;11(6):e867.

Srivastava BS, Singh VK, Kashyap VK, et al. Commentary: Bettering BCG: a toughtask for a tuberculosis vaccine? Front Immunol 2019;10:2195.

Romano M, Squeglia F, Kramarska E, et al. A structural view at vaccine development against M.tuberculosis. Cells 2023;12(2):317.

Counoupas C, Pinto R, Nagalingam G, et al. Delta inulin-based adjuvants promote the generation of polyfunctional CD4(+) T cell responses and protection against Mycobacterium tuberculosis infection. Sci Rep 2017;7(1):8582.

Liu X, Peng J, Hu L, et al. A multistage Mycobacterium tuberculosis subunit vaccine LT70 including latency antigen Rv2626c induces long-term protection against tuberculosis. Hum Vaccin Immunother 2016;12(7):1670-7.

Ma J, Teng X, Wang X, et al. A multistage subunit vaccine effectively protects mice against primary progressive tuberculosis, latency and reactivation. EBioMedicine 2017;22:143-54.

Aagaard C, Knudsen NPH, Sohn I, et al. Immunization with Mycobacterium tuberculosis-specific antigens bypasses T cell differentiation from prior bacillus Calmette-Guerin vaccination and improves protection in mice. J Immunol (Baltimore, Md:1950) 2020;205(8):2146-55.

Woodworth JS, Clemmensen HS, Battey H, et al. A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guerin. Nat Commun 2021;12(1):6658.

Cheng P, Xue Y, Wang J, et al. Evaluation of the consistence between the results of immunoinformatics predictions and real-world animal experiments of a new tuberculosis vaccine MP3RT. Front Cell Infect Microbiol 2022;12:1047306.

Van Der Meeren O, Hatherill M, Nduba V, et al. Phase 2b controlled trial of M72/AS01(E) vaccine to prevent tuberculosis. N Engl J Med 2018;379(17):1621-34.

Dillon DC, Alderson MR, Day CH, et al. Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family. Infect Immun 1999;67(6):2941-50.

Skeiky YA, Lodes MJ, Guderian JA, et al. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect Immun 1999;67(8):3998-4007.

Al-Attiyah R, Mustafa AS, Abal AT, et al. In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin Exp Immunol 2004;138(1):139-44.

Penn-Nicholson A, Geldenhuys H, Burny W, et al. Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. Vaccine 2015;33(32):4025-34.

Tait DR, Hatherill M, Van Der Meeren O, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med 2019;381(25):2429-39.

Brazier B, McShane H. Towards new tuberculosis vaccines. Semin Immunopathol 2020;42(3):315-31.

McShane H. Insights and challenges in tuberculosis vaccine development. Lancet Respir Med 2019;7(9):810-9.

Dagnew AF, Han LL, Naidoo K, et al. Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial. Lancet HIV 2025;12(8):E546-E555.

Tkachuk AP, Gushchin VA, Potapov VD, et al. Multi-subunit BCG booster vaccine GamTBvac: assessment of immunogenicity and protective efficacy in murine and guinea pig TB models. PLoS One 2017;12(4):e0176784.

Vasina DV, Kleymenov DA, Manuylov VA, et al. First-in-human trials of GamTBvac, a recombinant subunit tuberculosis vaccine candidate: Safety and immunogenicity assessment. Vaccines (Basel) 2019;7(4):166.

Tkachuk AP, Bykonia EN, Popova LI, et al. Safety and immunogenicity of the GamTBvac, the recombinant subunit tuberculosis vaccine candidate: a phase II, multi-center, double-blind, randomized, placebo-controlled study. Vaccines (Basel) 2020;8(4):652.

Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011;17(2):189-94.

Schellack C, Prinz K, Egyed A, et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006;24(26):5461-72.

Tait D, Diacon A, Borges AH, et al. Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial. J Infect Dis 2024;230(5):1262-70.

Li F, Dang W, Du Y, et al. Tuberculosis vaccines and T cell immune memory. Vaccines (Basel) 2024;12(5):483.

Baldwin SL, Reese VA, Huang PW, et al. Protection and long-lived immunity induced by the ID93/GLA-SE vaccine candidate against a clinical Mycobacterium tuberculosis isolate. Clin Vaccine Immunol 2016;23(2):137-47.

Coler RN, Day TA, Ellis R, et al. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines 2018;3:34.

Penn-Nicholson A, Tameris M, Smit E, et al. Safety and immunogenicity of the novel tuberculosis vaccine ID93+GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respir Med 2018;6(4):287-98.

Day TA, Penn-Nicholson A, Luabeya AKK, et al. Safety and immunogenicity of the adjunct therapeutic vaccine ID93+GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respir Med 2021;9(4):373-86.

Asokanathan C, Corbel M, Xing D. A CpG-containing oligodeoxynucleotide adjuvant for acellular pertussis vaccine improves the protective response against Bordetella pertussis. Hum Vaccin Immunother 2013;9(2):325-31.

Rapulana AM, Mpotje T, Baiyegunhi OO, et al. Combined analysis of host IFN-γ, IL-2 and IP-10 as potential LTBI biomarkers in ESAT-6/CFP-10 stimulated blood. Front Mol Med 2024;4:1345510.

Weeratna RD, McCluskie MJ, Xu Y, et al. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000;18(17):1755-62.

Lu JB, Chen BW, Wang GZ, et al. Recombinant tuberculosis vaccine AEC/BC02 induces antigen-specific cellular responses in mice and protects guinea pigs in a model of latent infection. J Microbiol Immunol Infect 2015;48(6):597-603.

Geldenhuys H, Mearns H, Miles DJ, et al. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: a randomized controlled trial. Vaccine 2015;33(30):3592-9.

Norrby M, Vesikari T, Lindqvist L, et al. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: two phase I dose escalation trials. Vaccine 2017;35(12):1652-61.

Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M.tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med 2018;379(2):138-49.

Lopez J, Anna F, Authie P, et al. A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4(+) T cell immunity. Cell Rep 2022;40(4):111142.

Hu Z, Wong KW, Zhao HM, et al. Sendai virus mucosal vaccination establishes lung-resident memory CD8 T cell immunity and boosts BCG-primed protection against TB in mice. Mol Ther 2017;25(5):1222-33.

Hu Z, Xia J, Wu J, et al. A multistage Sendai virus vaccine incorporating latency-associated antigens induces protection against acute and latent tuberculosis. Emerg Microbes Infect 2024;13(1):2300463.

Hoseinpour R, Hasani A, Baradaran B, et al. Tuberculosis vaccine developments and efficient delivery systems: a comprehensive appraisal. Heliyon 2024;10(4):e26193.

Hawkridge T, Scriba TJ, Gelderbloem S, et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis 2008;198(4):544-52.

Scriba TJ, Tameris M, Mansoor N, et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis 2011;203(12):1832-43.

Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013;381(9871):1021-8.

Nemes E, Hesseling AC, Tameris M, et al. Safety and immunogenicity of newborn MVA85A vaccination and selective, delayed Bacille Calmette-Guerin for infants of human immunodeficiency virus-infected mothers: a phase 2 randomized, controlled trial. Clin Infect Dis 2018;66(4):554-63.

Wilkie M, Satti I, Minhinnick A, et al. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1.85A prime-MVA85A boost in healthy UK adults. Vaccine 2020;38(4):779-89.

Pinpathomrat N, Bull N, Pasricha J, et al. Using an effective TB vaccination regimen to identify immune responses associated with protection in the murine model. Vaccine 2021;39(9):1452-62.

Wajja A, Nassanga B, Natukunda A, et al. Safety and immunogenicity of ChAdOx1.85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial. Lancet Infect Dis 2024;24(3):285-96.

Smaill F, Xing Z. Human type 5 adenovirus-based tuberculosis vaccine: is the respiratory route of delivery the future? Expert Rev Vaccines 2014;13(8):927-30.

Wang J, Thorson L, Stokes RW, et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol (Baltimore, Md: 1950) 2004;173(10):635765.

Smaill F, Jeyanathan M, Smieja M, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 2013;5(205):205ra134.

Weerasuriya CK, Clark RA, White RG, et al. New tuberculosis vaccines: advances in clinical development and modelling. J Intern Med 2020;288(6):661-81.

Abel B, Tameris M, Mansoor N, et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 2010;181(12):1407-17.

Srivastava S, Dey S, Mukhopadhyay S. Vaccines against tuberculosis: Where are we now? Vaccines (Basel) 2023;11(5):1013.

Jiang H, Luo TL, Kang J, et al. Expression of Rv2031c-Rv2626c fusion protein in Mycobacterium smegmatis enhances bacillary survival and modulates innate immunity in macrophages. Mol Med Rep 2018;17(5):7307-12.

Shurygina AP, Zabolotnykh N, Vinogradova T, et al. Preclinical evaluation of TB/FLU-04L-An intranasal influenza vector-based boost vaccine against tuberculosis. Int J Mol Sci 2023;24(8):7439.

Buzitskaya Z, Stosman K, Khairullin B, et al. A new intranasal influenza vector-based vaccine TB/FLU-04L against tuberculosis: preclinical safety studies. Drug Res 2022;72(5):255-8.

Stosman K, Sivak K, Aleksandrov A, et al. Preclinical safety evaluation: acute and repeated-dose toxicity of a new intranasal recombinant vector vaccine TB/FLU-04L against tuberculosis. Drug Research 2022;72(4):215-9.

Vasilyev K, Shurygina AP, Zabolotnykh N, et al. Enhancement of the local CD8+ T-cellular immune response to Mycobacterium tuberculosis in BCG-primed mice after intranasal administration of influenza vector vaccine carrying TB10.4 and HspX antigens. Vaccines 2021;9:1273.

Sergeeva M, Romanovskaya-Romanko E, Zabolotnyh N, et al. Mucosal influenza vector vaccine carrying TB10.4 and HspX antigens provides protection against Mycobacterium tuberculosis in mice and guinea pigs. Vaccines 2021;9:394.

Silva CL, Malardo T, Tahyra ASC. Immunotherapeutic activities of a DNA plasmid carrying the mycobacterial hsp65 gene (DNAhsp65). Front Med Technol 2020;2:603690.

Silva CL, Bonato VL, Lima VM, et al. Characterization of the memory/activated T cells that mediate the long-lived host response against tuberculosis after bacillus Calmette-Guerin or DNA vaccination. Immunology 1999;97(4):573-81.

Zarate-Blades CR, Rodrigues RF, Souza PR, et al. Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis. Hum Vaccin Immunother 2013;9(5):1093-103.

Goncalves ED, Bonato VL, da Fonseca DM, et al. Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming. Genet Vaccines Ther 2007;5:7.

Chen Y, Liu Q, Zhou L, et al. Emerging SARS-CoV-2 variants: Why, how, and what’s next? Cell Insight 2022;1(3):100029.

Pollard C, De Koker S, Saelens X, et al. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol Med 2013;19(12):705-13.

Linares-Fernández S, Lacroix C, Exposito JY, et al. Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends Mol Med 2020;26(3):311-23.

Larsen SE, Erasmus JH, Reese VA, et al. An RNA-based vaccine platform for use against Mycobacterium tuberculosis. Vaccines (Basel) 2023;11(1):130.

Rais M, Abdelaal H, Reese VA, et al. Immunogenicity and protection against Mycobacterium avium with a heterologous RNA prime and protein boost vaccine regimen. Tuberculosis (Edinb) 2023;138:102302.

Chugh S, Bahal RK, Dhiman R, et al. Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccinedevelopment. NPJ Vaccines 2024;9(1):57.

Li LS, Yang L, Zhuang L, et al. From immunologytoartificialintelligence: revolutionizing latent tuberculosis infectiondiagnosis with machinelearning. Mil Med Res 2023;10(1):58.

Zhuang L, Yang L, Li L, et al. Mycobacterium tuberculosis:immune response, biomarkers, and therapeutic intervention. MedComm 2024;5(1):e419.

Mangtani P, Abubakar I, Ariti C, et al.Protection by BCG vaccine against tuberculosis: a systematic review ofrandomizedcontrolledtrials. Clin Infect Dis 2014;58(4):470–80.

Newport MJ, Goetghebuer T, Weiss HA, et al. Genetic regulation of immune responses to vaccines in earlylife.Genes Immun 2004;5(2):122-9.

Andersen P, Doherty TM. The success and failure of BCG-implicationsfor a novel tuberculosis vaccine. Nat Rev Microbiol 2005;3(8):656-62.

Hosseinian K, Gerami A, Bral M, et al. Mycobacterium tuberculosis-Human Immunodeficiency Virus infection and the roleof T cells in protection. Vaccines (Basel) 2024;12(7):730.

Schrager LK, Vekemens J, Drager N, et al. The status of tuberculosis vaccine development. Lancet Infect Dis2020;20(3):e28–37.

Churchyard GJ, Houben R, Fielding K, et al. Implications of subclinical tuberculosis for vaccine trial designand global effect. Lancet Microbe 2024;5(10):100895.

Zhu Z, Zhang L, Li S, et al. S-6P exhibitsbetterimmunogenicitythan S-2P at lower doses of COVID-19 mRNA vaccines.Decoding Infect Transm2024;2:100017.

Khoshnood S, Heidary M, Haeili M, et al. Novel vaccine candidates against Mycobacterium tuberculosis. Int J Biol Macromol 2018;120(Pt A):180-8.

Ghattas M, Dwivedi G, Lavertu M, et al. Vaccine technologiesandplatforms for infectious diseases: current progress, challenges, andopportunities. Vaccines (Basel) 2021;9(12):1490.

Sarkar K, Kumar M, Jha A, et al. Nanocarriersfortuberculosis therapy: Design of safe and effective drug delivery strategiestoovercome the therapeutic challenges. J Drug Deliv Sci Technol2022;67:102850.

Giersing B, Shah N, Kristensen D, et al. Strategies for vaccine-productinnovation: creating an enablingenvironment for product development to uptake in low- and middleincomecountries. Vaccine 2021;39(49):7208-19.

Published

November 17, 2026

License

License